First recombinant trivalent seasonal influenza vaccine developed with VLP cell culture technology in the world.
Induces robust humoral response to all included strains-Antibody responses achieved are believed to be associated with reduced risk of influenza and its complications.
Provides seroprotection rates (≥70%) against all 3 strains Free from egg proteins safe in individuals with egg allergy Free from intact viral genome Non- infectious.
